2/26
03:27 am
gkos
Should Glaukos' (GKOS) Big 2026 Sales Target and ESOP Shelf Filing Require Action From Investors? [Yahoo! Finance]
Low
Report
Should Glaukos' (GKOS) Big 2026 Sales Target and ESOP Shelf Filing Require Action From Investors? [Yahoo! Finance]
2/21
02:08 am
gkos
Glaukos Corporation Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Glaukos Corporation Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/18
08:13 am
gkos
Glaukos (NYSE:GKOS) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $131.00 price target on the stock.
High
Report
Glaukos (NYSE:GKOS) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $131.00 price target on the stock.
2/18
08:06 am
gkos
Glaukos (NYSE:GKOS) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.
High
Report
Glaukos (NYSE:GKOS) had its "buy" rating reaffirmed by analysts at Needham & Company LLC.
2/18
07:01 am
gkos
Glaukos (NYSE:GKOS) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
High
Report
Glaukos (NYSE:GKOS) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
2/18
12:19 am
gkos
Glaukos Corp (GKOS) Q4 2025 Earnings Call Highlights: Record Sales and Strong Growth Outlook [Yahoo! Finance]
High
Report
Glaukos Corp (GKOS) Q4 2025 Earnings Call Highlights: Record Sales and Strong Growth Outlook [Yahoo! Finance]
2/17
11:18 pm
gkos
Glaukos outlines 2026 sales target of $600M–$620M as iDose TR and Epioxa drive growth momentum [Seeking Alpha]
High
Report
Glaukos outlines 2026 sales target of $600M–$620M as iDose TR and Epioxa drive growth momentum [Seeking Alpha]
2/17
11:18 pm
gkos
Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript [Seeking Alpha]
High
Report
Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript [Seeking Alpha]
2/17
10:47 pm
gkos
Glaukos Q4 Earnings Call Highlights [Yahoo! Finance]
High
Report
Glaukos Q4 Earnings Call Highlights [Yahoo! Finance]
2/17
07:10 pm
gkos
Glaukos (GKOS) Reports Q4 Loss, Beats Revenue Estimates [Yahoo! Finance]
High
Report
Glaukos (GKOS) Reports Q4 Loss, Beats Revenue Estimates [Yahoo! Finance]
2/17
06:40 pm
gkos
Glaukos (GKOS) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
High
Report
Glaukos (GKOS) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
2/17
04:45 pm
gkos
Glaukos: Q4 Earnings Snapshot [Yahoo! Finance]
High
Report
Glaukos: Q4 Earnings Snapshot [Yahoo! Finance]
2/17
04:05 pm
gkos
Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results
High
Report
Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results
2/4
04:27 pm
gkos
iVeena Delivery Systems Announces Strategic Leadership Promotions to Accelerate Growth and Scientific Innovation [Yahoo! Finance]
Low
Report
iVeena Delivery Systems Announces Strategic Leadership Promotions to Accelerate Growth and Scientific Innovation [Yahoo! Finance]
2/3
07:12 am
gkos
Glaukos (NYSE:GKOS) was upgraded by analysts at William Blair to a "strong-buy" rating.
Low
Report
Glaukos (NYSE:GKOS) was upgraded by analysts at William Blair to a "strong-buy" rating.
2/2
12:20 am
gkos
A Look At Glaukos (GKOS) Valuation After FDA Label Expansion For iDose TR [Yahoo! Finance]
Low
Report
A Look At Glaukos (GKOS) Valuation After FDA Label Expansion For iDose TR [Yahoo! Finance]
2/1
10:36 pm
gkos
Assessing Glaukos (GKOS) After Recent Share Price Rebound And DCF Upside Potential [Yahoo! Finance]
Low
Report
Assessing Glaukos (GKOS) After Recent Share Price Rebound And DCF Upside Potential [Yahoo! Finance]
2/1
07:51 pm
gkos
How Investors May Respond To Glaukos (GKOS) FDA-Backed Repeat Protocol For iDose TR Implant [Yahoo! Finance]
Low
Report
How Investors May Respond To Glaukos (GKOS) FDA-Backed Repeat Protocol For iDose TR Implant [Yahoo! Finance]
1/31
07:03 pm
gkos
Director Sells GKOS 15,000 Shares for $1.9 Million [Yahoo! Finance]
Low
Report
Director Sells GKOS 15,000 Shares for $1.9 Million [Yahoo! Finance]
1/29
10:32 am
gkos
Wells sees potential upside after Glaukos' iDose repeat dosing label approved [Yahoo! Finance]
Low
Report
Wells sees potential upside after Glaukos' iDose repeat dosing label approved [Yahoo! Finance]
1/28
12:50 pm
gkos
Glaukos (NYSE:GKOS) had its price target raised by analysts at BTIG Research from $123.00 to $131.00. They now have a "buy" rating on the stock.
Low
Report
Glaukos (NYSE:GKOS) had its price target raised by analysts at BTIG Research from $123.00 to $131.00. They now have a "buy" rating on the stock.
1/28
08:27 am
gkos
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR [Yahoo! Finance]
Low
Report
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR [Yahoo! Finance]
1/28
07:00 am
gkos
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
Medium
Report
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
1/23
08:06 am
gkos
What Makes Glaukos (GKOS) a Good Investment? [Yahoo! Finance]
Medium
Report
What Makes Glaukos (GKOS) a Good Investment? [Yahoo! Finance]
1/22
08:06 am
gkos
Glaukos (NYSE:GKOS) had its price target raised by analysts at Stifel Nicolaus from $115.00 to $160.00. They now have a "buy" rating on the stock.
Low
Report
Glaukos (NYSE:GKOS) had its price target raised by analysts at Stifel Nicolaus from $115.00 to $160.00. They now have a "buy" rating on the stock.